2024
Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Siwakoti A, Khadka S, Grimshaw A, Giri S. Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e870-e877. PMID: 39179448, DOI: 10.1016/j.clml.2024.07.008.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaProgression free survivalImpact of immunoparesisVisual examination of funnel plotsAssociated with worse OSOverall survivalMultiple myelomaFree survivalPrognostic impactPre-published protocolFunnel plotMeta-analysisHazard ratioTreatment outcomes of patientsPublication biasOutcomes of patientsContour-enhanced funnel plotsImmune system perturbationsInfection rateCause of mortalityInfection riskMicro AbstractClinical outcomesImmunoparesisPolyclonal immunoglobulins
2023
The Impact Of Immunoparesis On Outcomes Of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review
Siwakoti A, Khadka S, Grimshaw A, Giri S. The Impact Of Immunoparesis On Outcomes Of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review. Journal Of Allergy And Clinical Immunology 2023, 151: ab78. DOI: 10.1016/j.jaci.2022.12.248.Peer-Reviewed Original Research
2021
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.Peer-Reviewed Original ResearchConceptsConditioning regimen intensityAllo-HCTRegimen intensityChronic graftTransplant characteristicsGraft failureOverall survivalPatient ageSubgroup analysisDynamic International Prognostic Scoring System scoresSystematic reviewAllogeneic hematopoietic cell transplantationInternational Prognostic Scoring System scoreCurative therapeutic modalityNon-relapse mortalityTransplant-related mortalityMedian patient ageOutcomes of patientsSecondary graft failureCo-primary outcomesHematopoietic cell transplantHematopoietic cell transplantationRandomized clinical trialsHeterogeneity of patientsRandom-effects model